The Trouble With KRAS - Cancer Commons
KRAS and extended RAS molecular profiling in metastatic colorectal cancer | Colorectal Cancer
KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study | BMJ Open
Frontiers | Targeting KRAS: The Elephant in the Room of Epithelial Cancers
KRAS Codon 12 Mutation is Associated with More Aggressive Invasiveness | OTT
Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan | BMC Cancer | Full Text
Personalized Cancer Treatment and the Myth of KRAS Wild-type Colon Tumors - Barbara L Parsons - Discovery Medicine
KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer - The Lancet Oncology
ADAM17-Dependent c-MET-STAT3 Signaling Mediates Resistance to MEK Inhibitors in KRAS Mutant Colorectal Cancer: Cell Reports
Targeting EGFR in metastatic colorectal cancer beyond the limitations of KRAS status: alternative biomarkers and therapeutic strategies | Biomarkers in Medicine
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer | Molecular Cancer | Full Text
APMG Colon Molecular Pathways
The current understanding on the impact of KRAS on colorectal cancer - ScienceDirect
Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer | Semantic Scholar
Prevalence of KRAS, NRAS and BRAF mutations in patients with colorectal... | Download Scientific Diagram
KRAS Biomarker | Colorectal Cancer Alliance
The mutation distribution of KRAS/NRAS/BRAF in (A) colon cancer, (B)... | Download Scientific Diagram
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C | NEJM
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer | Molecular Cancer | Full Text
TAK1 Inhibition Promotes Apoptosis in KRAS-Dependent Colon Cancers - ScienceDirect
,0.jpg "Progress towards individualized treatment of colorectal cancer UAB Barcelona")
Progress towards individualized treatment of colorectal cancer UAB Barcelona
Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer
VisualAbstract: Adagrasib provides antitumour activity against KRAS G12C mutant metastatic colorectal cancer both as monotherapy and in combination with cetuximab | 2 Minute Medicine
IJMS | Free Full-Text | Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer
Frontiers | Molecular Network of Colorectal Cancer and Current Therapeutic Options
